Pharvaris Presents Deucrictibant Data at CIIC Conference
Pharvaris presented data evaluating safety margins of administration of deucrictibant immediate-release, or IR, capsule in combination with deucrictibant extended-release, or XR, tablet at the Consortium of Independent Immunology Clinics, or CIIC, Spring 2026 Conference, which took place from April 17-19, 2026, in Arlington, TX. A recently published post-hoc analysis of the prophylaxis CHAPTER-1 study assessed the mean duration of breakthrough attacks, in both placebo and deucrictibant arms, that were treated with a single dose of icatibant, another bradykinin B2 receptor antagonist. The comparable mean total duration of icatibant-treated attacks in the placebo-icatibant and the deucrictibant-icatibant groups provide initial evidence on the efficacy of combining use of a bradykinin B2 receptor antagonist for prophylaxis and on-demand treatment of attacks.
